BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expanding its rare-disease business with the acquisition of Alesta Therapeutics for $275 million upfront. The deal gives BioMarin access to ALE1, an oral treatment being developed for hypophosphatasia (HPP), a rare genetic bone disorder.ALE1 is still in early-stage clinical trials, so there is a long way to go before it could reach the market. But if the drug delivers positive results, it could become the first oral treatment for HPP. BioMarin could also pay Ale ...